[go: up one dir, main page]

AR044802A1 - Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos - Google Patents

Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos

Info

Publication number
AR044802A1
AR044802A1 ARP040102112A ARP040102112A AR044802A1 AR 044802 A1 AR044802 A1 AR 044802A1 AR P040102112 A ARP040102112 A AR P040102112A AR P040102112 A ARP040102112 A AR P040102112A AR 044802 A1 AR044802 A1 AR 044802A1
Authority
AR
Argentina
Prior art keywords
pharmaceutically acceptable
acceptable salts
acid derivatives
carboxyl acid
dyslipidemias
Prior art date
Application number
ARP040102112A
Other languages
English (en)
Inventor
Ralf Ragnar
Erica Stahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR044802A1 publication Critical patent/AR044802A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/18—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides
    • C07C235/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a una sal de calcio o magnesio de ácido (2S)-2-etoxi-3-(4-{2[hexil(2-feniletil)amino]-2-oxoetoxi]fenil)propanoico, a procesos para preparar dichos compuestos, utilidad en el tratamiento de afecciones clínicas que incluyen trastornos en los lípidos (dislipidemias) asociados o no a la resistencia a la insulina y otras manifestaciones del síndrome metabólico, a métodos para su uso terapéutico y a composiciones farmacéuticas que las contienen.
ARP040102112A 2003-06-18 2004-06-17 Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos AR044802A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0314136.3A GB0314136D0 (en) 2003-06-18 2003-06-18 Therapeutic agents

Publications (1)

Publication Number Publication Date
AR044802A1 true AR044802A1 (es) 2005-10-05

Family

ID=27636795

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102112A AR044802A1 (es) 2003-06-18 2004-06-17 Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos

Country Status (21)

Country Link
US (1) US20060194879A1 (es)
EP (1) EP1638921A1 (es)
JP (1) JP3836498B1 (es)
KR (1) KR20060017646A (es)
CN (1) CN1805922A (es)
AR (1) AR044802A1 (es)
AU (1) AU2004247611A1 (es)
BR (1) BRPI0411455A (es)
CA (1) CA2527608A1 (es)
CO (1) CO5650229A2 (es)
GB (1) GB0314136D0 (es)
IL (1) IL172168A0 (es)
IS (1) IS8232A (es)
MX (1) MXPA05013713A (es)
NO (1) NO20055923L (es)
RU (1) RU2005138369A (es)
SA (1) SA04250170B1 (es)
TW (1) TW200503678A (es)
UY (1) UY28371A1 (es)
WO (1) WO2004110985A1 (es)
ZA (1) ZA200510199B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229931D0 (en) * 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
GB0314079D0 (en) * 2003-06-18 2003-07-23 Astrazeneca Ab Therapeutic agents
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
SE0104333D0 (sv) 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
DK1517883T3 (da) 2002-06-20 2008-05-26 Astrazeneca Ab Ortho-substituerede benzoesyrederivater til behandling af insulinresistens
WO2007004957A1 (en) * 2005-07-05 2007-01-11 Astrazeneca Ab Novel crystalline form
AR055073A1 (es) * 2005-07-11 2007-08-01 Astrazeneca Ab Agentes terapeuticos
FR2903985B1 (fr) 2006-07-24 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
FR2904316B1 (fr) 2006-07-31 2008-09-05 Sanofi Aventis Sa Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
PE20081463A1 (es) * 2006-10-20 2008-10-18 Janssen Pharmaceutica Nv Formas salinas de compuestos de benzotienilo sustituido

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU760163B2 (en) * 1999-04-06 2003-05-08 Sankyo Company Limited Alpha-substituted carboxylic acid derivatives
SE0104334D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
RU2005138369A (ru) 2007-07-27
JP2006527767A (ja) 2006-12-07
US20060194879A1 (en) 2006-08-31
MXPA05013713A (es) 2006-06-27
WO2004110985A1 (en) 2004-12-23
CO5650229A2 (es) 2006-06-30
EP1638921A1 (en) 2006-03-29
CN1805922A (zh) 2006-07-19
UY28371A1 (es) 2005-01-31
IL172168A0 (en) 2009-02-11
AU2004247611A1 (en) 2004-12-23
CA2527608A1 (en) 2004-12-23
NO20055923L (no) 2006-01-06
IS8232A (is) 2006-01-13
TW200503678A (en) 2005-02-01
KR20060017646A (ko) 2006-02-24
BRPI0411455A (pt) 2006-07-18
ZA200510199B (en) 2006-12-27
JP3836498B1 (ja) 2006-10-25
SA04250170B1 (ar) 2007-10-29
GB0314136D0 (en) 2003-07-23

Similar Documents

Publication Publication Date Title
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
ES2611483T3 (es) Agente terapéutico para enfermedad inflamatoria intestinal
SG10201407013QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
CR9587A (es) Derivados de piridazina
AR070357A1 (es) Producto para cuidado oral y metodos de uso y manufactura del mismo
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CY1108700T1 (el) Συνθεσεις απελευθερωσης φαρμακου εστερα αλφα-υδροξυ οξεος και μεθοδοι χρησης
CR20120605A (es) Formulación tópica para un inhibidor de jak
CR9703A (es) Derivados de pirazolona
UA92181C2 (ru) Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера
AR080491A1 (es) Formulaciones orales y sales lipofilicas de metilnaltrexona
ES2496669T3 (es) Agentes antitumorales con una estructura de benzofenantridina y formulaciones que los contienen
NI200800227A (es) Acidos 1,3-dioxano carboxilicos
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
AR044802A1 (es) Sales farmaceuticamente aceptables, de derivados de acidos carboxilicos
AR069508A1 (es) Derivados de quinolina 057; un proceso para su preparacion; una composicion farmaceutica; la preparacion de esta y el uso del compuesto para preparar un medicamento
PE20141539A1 (es) Una nueva composicion terapeutica que contiene apomorfina como principio activo
AR062659A1 (es) Composicion de liberacion sostenida de levodopa y metodo para su uso
AR060568A1 (es) Acidos bifenilcarboxilicos substituidos y sus derivados
ES2531516T3 (es) Uso de escina
AR029412A1 (es) Forma cristalina
UY29065A1 (es) Derivados del ácido alcanoico arilcicloalquil-sustituidos, procedimientos para su preparación y su uso como productos farmacéuticos.
EA200702072A1 (ru) Фенилсодержащие n-ацильные производные аминов и аминокислот, способ их получения, фармацевтическая композиция и их применение
PE20030277A1 (es) Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
CO6592037A2 (es) Combinación de un aine y un aminoacido

Legal Events

Date Code Title Description
FA Abandonment or withdrawal